Protection against lethal influenza with a viral mimic

Journal of Virology

Volumn 87, Issue 15, 2013, Pages 8591-8605

  Baker, Steven F ^a   Guo, Hailong ^a   Albrecht, Randy A ^c   García Sastre, Adolfo ^c   Topham, David J ^a,b   Martínez Sobrido, Luis ^a,b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; MALE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROGENY; PROTEIN EXPRESSION; RECEPTOR BINDING; REVERSE GENETICS; SINGLE CYCLE INFECTIOUS INFLUENZA VIRUS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; FERRETS; HUMANS; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; REVERSE GENETICS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84880615843     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01081-13     Document Type: Article

References (49)

1. Lemey P, Suchard M, Rambaut A. 2009. Reconstructing the initial global spread of a human influenza pandemic: a Bayesian spatial-temporal model for the global spread of H1N1pdm. PLoS Curr. 1:RRN1031. doi:10.1371/currents.RRN1031.
2. Wright PF, Neumann G, Kawaoka Y. 2007. Orthomyxoviruses, p 1691-1740. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
3. Commission on Influenza, Board for the Investigation and Control of Influenza and Other Epidemic Diseases in the Army, Preventive Medicine Service, Office of the Surgeon General, United States Army. 1944. A clinical evaluation of vaccination against influenza. Joint Report with Members of the Commission on Influenza, Board for the Investigation and Control of Influenza and Other Epidemic Diseases in the Army, Preventive Medicine Service, Office of the Surgeon General, United States Army. JAMA 124:982-985.
4. Osterholm MT, Kelley NS, Sommer A, Belongia EA. 2012. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12:36-44.
5. Palese PS, Shaw ML. 2007. Orthomyxoviridae: the viruses and their replication, p 1647-1689. In Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE (ed), Fields virology, 5th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
6. WHO. 2009. Influenza (seasonal) fact sheet no. 211. WHO, Geneva, Switzerland.
7. Sun W. 2012. Approval letter-Fluarix Quadrivalent (BL 125127/513). U.S. Food and Drug Administration (FDA), Silver Spring, MD.
8. Sun W. 2012. Approval letter-FluMist® Quadrivalent (BL 125020/1668). U.S. Food and Drug Administration (FDA), Silver Spring, MD.
9. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO. 2012. A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. U. S. A. 109:4269-4274.
10. Dowdle WN, Kendal AP, Noble GR. 1979. Influenza viruses, p 585-609. In Lennette EH, Schmidt NJ (ed), Diagnostic procedures for viral, rickettsial, and chlamydial infections, 5th ed. American Public Health Association, Washington, DC.
11. Centers for Disease Control and Prevention (CDC). 2012. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. MMWR Morb. Mortal. Wkly. Rep. 61:613-618.
12. Martínez-Sobrido L, Cadagan R, Steel J, Basler CF, Palese P, Moran TM, Garcia-Sastre A. 2010. Hemagglutinin-pseudotyped green fluorescent protein-expressing influenza viruses for the detection of influenza virus neutralizing antibodies. J. Virol. 84:2157-2163.
13. Guo H, Santiago F, Lambert K, Takimoto T, Topham DJ. 2011. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J. Virol. 85:448-455.
14. Schickli JH, Flandorfer A, Nakaya T, Martinez-Sobrido L, Garcia-Sastre A, Palese P. 2001. Plasmid-only rescue of influenza A virus vaccine candidates. Philos. Trans. R. Soc. Lond. B Biol. Sci. 356:1965-1973.
15. Kilbourne ED. 1969. Future influenza vaccines and the use of genetic recombinants. Bull. World Health Organ. 41:643-645.
16. Polakos NK, Klein I, Richter MV, Zaiss DM, Giannandrea M, Crispe IN, Topham DJ. 2007. Early intrahepatic accumulation of CD8 T cells provides a source of effectors for nonhepatic immune responses. J. Immunol. 179:201-210.
17. Richards KA, Chaves FA, Krafcik FR, Topham DJ, Lazarski CA, Sant AJ. 2007. Direct ex vivo analyses of HLA-DR1 transgenic mice reveal an exceptionally broad pattern of immunodominance in the primary HLADR1-restricted CD4 T-cell response to influenza virus hemagglutinin. J. Virol. 81:7608-7619.
18. Chapman TJ, Castrucci MR, Padrick RC, Bradley LM, Topham DJ. 2005. Antigen-specific and non-specific CD4+ T cell recruitment and proliferation during influenza infection. Virology 340:296-306.
19. Hai R, Schmolke M, Varga ZT, Manicassamy B, Wang TT, Belser JA, Pearce MB, Garcia-Sastre A, Tumpey TM, Palese P. 2010. PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models. J. Virol. 84:4442-4450.
20. Marsh GA, Hatami R, Palese P. 2007. Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J. Virol. 81:9727-9736.
21. Medina RA, Manicassamy B, Stertz S, Seibert CW, Hai R, Belshe RB, Frey SE, Basler CF, Palese P, Garcia-Sastre A. 2010. Pandemic 2009 H1N1 vaccine protects against 1918 Spanish influenza virus. Nat. Commun. 1:28.
22. Steel J, Lowen AC, Pena L, Angel M, Solorzano A, Albrecht R, Perez DR, Garcia-Sastre A, Palese P. 2009. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J. Virol. 83:1742-1753.
23. Seibert CW, Kaminski M, Philipp J, Rubbenstroth D, Albrecht RA, Schwalm F, Stertz S, Medina RA, Kochs G, Garcia-Sastre A, Staeheli P, Palese P. 2010. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J. Virol. 84:11219-11226.
24. O'Neill RE, Talon J, Palese P. 1998. The influenza virus NEP (NS2 protein) mediates the nuclear export of viral ribonucleoproteins.EMBOJ. 17:288-296.
25. Lindenmann J, Burke DC, Isaacs A. 1957. Studies on the production, mode of action and properties of interferon. Br. J. Exp. Pathol. 38:551-562.
26. + T cell crossreactivity and specificities revealed after 2009 H1N1 influenza A virus infection in mice. PLoS One 7:e46166. doi:10.1371/journal.pone.0046166.
27. Chen Z, Wang W, Zhou H, Suguitan AL, Jr, Shambaugh C, Kim L, Zhao J, Kemble G, Jin H. 2010. Generation of live attenuated novel influenza virus A/California/7/09 (H1N1) vaccines with high yield in embryonated chicken eggs. J. Virol. 84:44-51.
28. Suphaphiphat P, Franti M, Hekele A, Lilja A, Spencer T, Settembre E, Palmer G, Crotta S, Tuccino AB, Keiner B, Trusheim H, Balabanis K, Sackal M, Rothfeder M, Mandl CW, Dormitzer PR, Mason PW. 2010. Mutations at positions 186 and 194 in the HA gene of the 2009 H1N1 pandemic influenza virus improve replication in cell culture and eggs. Virol. J. 7:157. doi:10.1186/1743-422X-7-157.
29. Liang S, Mozdzanowska K, Palladino G, Gerhard W. 1994. Heterosubtypic immunity to influenza type A virus in mice. Effector mechanisms and their longevity. J. Immunol. 152:1653-1661.
30. van Riel D, Munster VJ, de Wit E, Rimmelzwaan GF, Fouchier RA, Osterhaus AD, Kuiken T. 2007. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J. Pathol. 171:1215-1223.
31. Maher JA, DeStefano J. 2004. The ferret: an animal model to study influenza virus. Lab. Anim. (NY) 33:50-53.
32. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. 2002. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 54:99-111.
33. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. 2009. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 325:484-487.
34. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, van de Vijver D, Boucher CA, Koopmans M, Rimmelzwaan GF, Kuiken T, Osterhaus AD, Fouchier RA. 2009. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 325:481-483.
35. Van Hoeven N, Pappas C, Belser JA, Maines TR, Zeng H, Garcia-Sastre A, Sasisekharan R, Katz JM, Tumpey TM. 2009. Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc. Natl. Acad. Sci. U. S. A. 106:3366-3371.
36. Vu T, Farish S, Jenkins M, Kelly H. 2002. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine 20:1831-1836.
37. Falsey AR, Treanor JJ, Tornieporth N, Capellan J, Gorse GJ. 2009. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J. Infect. Dis. 200:172-180.
38. Centers for Disease Control and Prevention (CDC). 2010. Licensure of a high-dose inactivated influenza vaccine for persons aged 65 years (Fluzone High-Dose) and guidance for use-United States, 2010.MMWR Morb. Mortal. Wkly. Rep. 59:485-486.
39. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, Wolff M, Rabinovich G, Blackwelder W, Katz JM. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
40. Latham T, Galarza JM. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75:6154-6165.
41. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186:1022-1031.
42. Pushko P, Tumpey TM, Bu F, Knell J, Robinson R, Smith G. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/cmice. Vaccine 23:5751-5759.
43. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. 1999. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5:1157-1163.
44. Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, Sessions WM, Xu X, Skepner E, Deyde V, Okomo-Adhiambo M, Gubareva L, Barnes J, Smith CB, Emery SL, Hillman MJ, Rivailler P, Smagala J, de Graaf M, Burke DF, Fouchier RA, Pappas C, Alpuche-Aranda CM, Lopez-Gatell H, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325:197-201.
45. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, DeVos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. 2009. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N. Engl. J. Med. 361:1945-1952.
46. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, Lindstrom S, Shay DK. 2009. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J. Infect. Dis. 199:159-167.
47. Kohlmeier JE, Woodland DL. 2009. Immunity to respiratory viruses. Annu. Rev. Immunol. 27:61-82.
48. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, Randall TD, Kaminski DA. 2011. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J. Immunol. 186:4331-4339.
49. Gruber M. 2012. Approval letter-Flucelvax (BL 125408/0). U.S. Food and Drug Administration (FDA), Silver Spring, MD.